Immunocore Holdings plc (IMCR) UBS Global Biopharma Conference 2026 November 17, 2026 10:20 AM EST

Company Participants

Travis Coy – CFO, Executive VP & Head of Corporate Development

Conference Call Participants

Dina Elmonshed – UBS Investment Bank, Research Division

Presentation

Dina Elmonshed
UBS Investment Bank, Research Division

Hello, everyone. My name is Dina Elmonshed, one of the biotech analysts here at UBS, and I am excited and pleased to welcome Travis Coy, Chief Financial Officer of Immunocore. I am excited for us to get started on this.

Question-and-Answer Session

Dina Elmonshed
UBS Investment Bank, Research Division

And so maybe we can start with a couple of questions around the commercial business for KIMMTRAK.

Maybe just we are probably in our fourth year of launch now. And so given pretty peak penetration levels in especially OUS market and maybe 70% in the U.S. nearly there. So maybe just thinking about where are the remaining growth drivers, particularly in the community setting, both in the U.S. and OUS? And where do you see KIMMTRAK from here in the outer years?

Travis Coy
CFO, Executive VP & Head of Corporate Development

Yes. No, thanks, Dave. First of all, thank you for having me. Thank you for having us. So all good question on KIMMTRAK. We’re really pleased that KIMMTRAK has become the standard of care across all major markets. And you’re elaborating to some of the penetration levels we had. We’re at 70% plus penetration across all markets. And so as we look at the growth, naturally in this part of the product’s life cycle, we’re seeing growth begin to moderate. It’s a good thing, right? We did a good job on launch, right?

Dina Elmonshed
UBS Investment Bank, Research Division

Launched very quickly.

Travis Coy
CFO, Executive VP & Head of Corporate Development

Share.
Exit mobile version